RSS | Login | Register

Mood Disorder Treatments

January 12, 2010

Print
Email
Reprint
Permissions
Font Size: A | A | A

Mood Disorders (download)

MOOD DISORDERS

Generic & Class	Brand	Formulation(s)	Bipolar Disorder				Depression	TRD†	PMDD*	Others**
Generic & Class	Brand	Formulation(s)	Mania	Depression	Mixed Episodes	Maintenance	Depression	TRD†	PMDD*	Others**
ATYPICAL ANTIPSYCHOTICS
Aripiprazole	Abilify	tabs	√		√	√	√¹			√
		oral soln	√		√	√	√¹			√
		inj	√		√					√
	Abilify Discmelt	ODT	√		√	√	√¹			√
Asenapine	Saphris	sublingual tabs	√		√					√
Olanzapine	Zyprexa	tabs	√	√	√	√		√²		√
	Zyprexa	IM inj	√							√
	Zyprexa Zydis	ODT	√	√	√	√		√²		√
Quetiapine	Seroquel	tabs	√	√		√				√
Quetiapine	Seroquel XR	ext-rel tabs	√		√					√
Risperidone	Risperdal	tabs	√		√					√
	Risperdal	oral soln	√		√					√
	Risperdal M-tabs	ODT	√		√					√
Ziprasidone	Geodon	caps	√		√					√
COMBINATION ATYPICAL & SELECTIVE SEROTONIN REUPTAKE INHIBITOR
Olanzapine + fluoxetine	Symbyax	caps		√			√	√
MONOAMINE OXIDASE INHIBITORS (MAOIs)
Phenelzine	Nardil	tabs					√
Selegiline	EMSAM	transdermal patch					√
Tranylcypromine	Parnate	tabs					√
SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIs)
Desvenlafaxine	Pristiq	ext-rel tabs					√
Duloxetine	Cymbalta	caps					√			√
Venlafaxine	Effexor	tabs (+)					√
Venlafaxine	Effexor XR	ext-rel caps					√			√
SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs)
Citalopram	Celexa	tabs (+)					√
Citalopram	Celexa	oral soln					√
Escitalopram	Lexapro	tabs (+)					√			√
Escitalopram	Lexapro	oral soln					√			√
Fluoxetine	Prozac	caps		√			√	√³		√
	Prozac	oral soln		√			√	√³		√
	Prozac Weekly	del-rel caps					√
	Sarafem	caps							√
Paroxetine	Paxil	tabs (+)					√			√
	Paxil	oral susp					√			√
	Paxil CR	controlled-rel tabs					√		√	√
Sertraline	Zoloft	tabs (+)					√		√	√
Sertraline	Zoloft	oral conc					√		√	√
TETRACYCLIC ANTIDEPRESSANTS
Mirtazapine	Remeron	tabs (+)					√
Mirtazapine	Remeron Soltab	ODT					√
TRICYCLIC ANTIDEPRESSANTS (TCAs)
Amitriptyline	—	tabs					√
Desipramine	Norpramin	tabs					√
Doxepin	Sinequan	caps					√			√
Doxepin	Sinequan	oral conc					√			√
Imipramine	Tofranil	tabs					√			√
	Tofranil	inj					√
	Tofranil-PM	caps					√
Nortriptyline	Pamelor	caps					√
Nortriptyline	Pamelor	oral soln					√
Protriptyline	Vivactil	tabs					√
Trimipramine	Surmontil	caps					√
OTHER CLASSES
Bupropion HBr	Aplenzin	ext-rel tabs					√
Bupropion HCl	Wellbutrin	tabs					√
	Wellbutrin SR	sust-rel tabs					√
	Wellbutrin XL	ext-rel tabs					√
Carbamazepine	Equetro	ext-rel caps	√
Divalproex sodium	Depakote	del-rel tabs	√							√
Divalproex sodium	Depakote ER	ext-rel tabs	√							√
Lamotrigine	Lamictal	tabs (+)				√				√
Lamotrigine	Lamictal	chewable, dispersible tabs				√				√
Lithium carbonate	Lithobid	slow-rel tabs	√			√
Nefazodone	—	tabs (+)					√
Trazodone	Desyrel	tabs (+)					√
Valproic acid	Stavzor	del-rel caps	√
NOTES
†TRD = treatment resistant depression. PMDD = premenstrual dysphoric disorder. *Not a complete list of official indications or formulations. For a more complete description of -indications, see individual product entries and/or contact manufacturer for full labeling. ¹For adjunctive -treatment. ²For TRD, use in combination with fluoxetine. ³For TRD, use in combination with olanzapine. Caps = capsules; tabs = tablets; (+) = scored; ext-rel = extended-release; del-rel = delayed release; soln = solution; susp = suspension; inj = injection; conc = concentrate; ODT = orally-disintegrating tabs. (Rev. 2/2010)

| Share

FDA warns of aseptic meningitis risk with Lamictal

August 13, 2010

The FDA has informed healthcare professionals and patients that Lamictal (lamotrigine, from GlaxoSmithKline) can cause aseptic meningitis.

Oleptro available for major depressive disorder

August 10, 2010

Labopharm and Angelini announced the launch of Oleptro (trazodone HCl extended-release tablets) for the treatment of major depressive disorder (MDD) in adults.

Phase 3 study of TC-5214 for major depressive disorder (MDD)

June 23, 2010

AstraZeneca and Targacept announced the enrollment of the first patient in their Phase 3 development program for TC-5214 as an adjunct treatment for major depressive disorder (MDD) in patients with an inadequate response to first-line therapy with a selective serotonin reuptake inhibitor (SSRI) or serotonin/norepinephrine reuptake inhibitor (SNRI).

FDA launches "Bad Ad Program" to detect misleading drug ads

May 11, 2010

The FDA's Division of Drug Marketing, Advertising, and Communications (DDMAC) has launched the Bad Ad Program, designed to educate healthcare providers about their role in ensuring that prescription drug advertising and promotion is truthful, and not misleading.

NDA submitted for vilazodone for major depressive disorder (MDD)

March 23, 2010

Clinical Data Inc. announced that a New Drug Application (NDA) has been submitted to the FDA seeking approval of vilazodone for the treatment of major depressive disorder (MDD).